ImmunityBio, Inc. (IBRX) Tops Q4 EPS by 5c

ImmunityBio, Inc. (NASDAQ: IBRX) reported Q4 EPS of ($0.06), $0.05 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $38.28 million versus the consensus estimate of $35.99 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.

You May Also Be Interested In

• Texas Instruments (TXN) Reiterated at Neutral by Cantor Fitzgerald on Upside to Earnings Power
• Macy's (M) call put ratio 1 call to 1 put into release of quarter results
• SK Hynix (SKHY) call put ratio 1.2 calls to 1 put as share price up 4.7%